OTCPK:SART.F

Stock Analysis Report

Executive Summary

Sartorius Aktiengesellschaft supplies pharmaceutical and laboratory equipment worldwide.

Snowflake

Fundamentals

Reasonable growth potential with acceptable track record.


Similar Companies

Share Price & News

How has Sartorius's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-8.8%

SART.F

0.7%

US Medical Equipment

-0.2%

US Market


1 Year Return

n/a

SART.F

9.5%

US Medical Equipment

1.1%

US Market

No trading data on SART.F.

No trading data on SART.F.


Share holder returns

SART.FIndustryMarket
7 Day-8.8%0.7%-0.2%
30 Day-8.8%0.1%2.5%
90 Dayn/a2.5%1.6%
1 Yearn/a10.4%9.5%3.4%1.1%
3 Year111.6%111.6%69.3%64.1%45.2%35.8%
5 Yearn/a138.0%110.9%62.6%44.8%

Price Volatility Vs. Market

How volatile is Sartorius's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Sartorius undervalued based on future cash flows and its price relative to the stock market?

77.17x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

Sartorius's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

Sartorius's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

Sartorius is overvalued based on earnings compared to the US Medical Equipment industry average.

Sartorius is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

Sartorius is poor value based on expected growth next year.


Price Based on Value of Assets

Sartorius is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Sartorius expected to perform in the next 1 to 3 years based on estimates from 13 analysts?

17.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Sartorius's revenue is expected to grow by 10.5% yearly, however this is not considered high growth (20% yearly).

Sartorius's earnings are expected to grow by 17.6% yearly, however this is not considered high growth (20% yearly).

Sartorius's revenue growth is expected to exceed the United States of America market average.

Sartorius's earnings growth is expected to exceed the United States of America market average.

Sartorius's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Sartorius is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).


Next Steps

Past Performance

How has Sartorius performed over the past 5 years?

23.1%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Sartorius has delivered over 20% year on year earnings growth in the past 5 years.

Sartorius's 1-year earnings growth exceeds its 5-year average (32.1% vs 23.1%)

Sartorius's earnings growth has exceeded the US Medical Equipment industry average in the past year (32.1% vs 28.2%).


Return on Equity

Whilst Sartorius has efficiently used shareholders’ funds last year (Return on Equity greater than 20%), this is metric is skewed due to its high level of debt.


Return on Assets

Sartorius used its assets less efficiently than the US Medical Equipment industry average last year based on Return on Assets.


Return on Capital Employed

Sartorius's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Sartorius's financial position?


Financial Position Analysis

Sartorius is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Sartorius's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

Sartorius's level of debt (100.1%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has increased over the past 5 years (86% vs 100.1% today).

Debt is well covered by operating cash flow (31.1%, greater than 20% of total debt).

Interest payments on debt are well covered by earnings (EBIT is 28.8x coverage).


Balance Sheet

High level of physical assets or inventory.

Debt is not covered by short term assets, assets are 0.8x debt.


Next Steps

Dividend

What is Sartorius's current dividend yield, its reliability and sustainability?

0.58%

Expected Dividend Yield


Dividend Yield and Payments Analysis

Sartorius's pays a lower dividend yield than the bottom 25% of dividend payers in United States of America (1.44%).

Sartorius's dividend is below the markets top 25% of dividend payers in United States of America (3.71%).

Sartorius is not paying a notable dividend for United States of America, therefore no need to check if the payments are stable.

Sartorius is not paying a notable dividend for United States of America, therefore no need to check if the payments are increasing.


Current Payout to Shareholders

No need to calculate the sustainability of Sartorius's dividends as it is not paying a notable one for United States of America.


Future Payout to Shareholders

No need to calculate the sustainability of Sartorius's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of Sartorius's salary, the management and board of directors tenure and is there insider trading?

1.7yrs

Average management tenure


CEO

Joachim Kreuzburg (54yo)

16.3yrs

Tenure

€1,999,000

Compensation

Dr. rer. pol. Joachim Kreuzburg serves as the Chairman and Chief Executive Officer at Sartorius Stedim Biotech GmbH. Dr. rer. pol. Kreuzburg has been the Chairman of Executive Board at Sartorius Aktiengese ...


CEO Compensation Analysis

Joachim's remuneration is lower than average for companies of similar size in United States of America.

Joachim's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

1.7yrs

Average Tenure

50yo

Average Age

The average tenure for the Sartorius management team is less than 2 years, this suggests a new team.


Board Age and Tenure

7.4yrs

Average Tenure

62yo

Average Age

The tenure for the Sartorius board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Gerry Mackay (56yo)

    Head of Lab Products & Services Division and Member of Executive Board

    • Tenure: 0.7yrs
  • Manfred Werner

    Senior Vice President of Administration Organization & Auditing

    • Tenure: 0yrs
  • Mei Wang

    Head of Production - China

    • Tenure: 0yrs
  • Patricia Spannagel

    Head of Quality Assurance - Mechatronics Division Goettingen

    • Tenure: 0yrs
  • Rashid Maqbool

    Head of Production & Certification Department - Denver USA

    • Tenure: 0yrs
  • Manohar Kuppusami

    Head of Production Department - India

    • Tenure: 0yrs
  • Joachim Kreuzburg (54yo)

    Chairman of Executive Board & CEO

    • Tenure: 16.3yrs
    • Compensation: €2.00m
  • Petra Kirchhoff (50yo)

    Head of Corporate Communications & Investor Relations and Member of Supervisory Board

    • Tenure: 0yrs
    • Compensation: €46.00k
  • Rainer Lehmann (43yo)

    CFO & Member of Executive Board and Head of Finance

    • Tenure: 1.7yrs
    • Compensation: €1.04m
  • René Fáber (43yo)

    Head of Bioprocess Solutions Division & Member of Executive Board

    • Tenure: 0.7yrs

Board Members

  • Klaus Trützschler (71yo)

    Member of Supervisory Board

    • Tenure: 7.8yrs
    • Compensation: €90.00k
  • Uwe Bretthauer

    Member of Supervisory Board

    • Tenure: 0yrs
    • Compensation: €82.00k
  • Annette Becker (55yo)

    Member of the Supervisory Board

    • Tenure: 0yrs
    • Compensation: €46.00k
  • Petra Kirchhoff (50yo)

    Head of Corporate Communications & Investor Relations and Member of Supervisory Board

    • Tenure: 0yrs
    • Compensation: €46.00k
  • Michael Dohrmann (63yo)

    Member of the Supervisory Board

    • Tenure: 12.8yrs
    • Compensation: €46.00k
  • Lothar Kappich (62yo)

    Chairman of Supervisory Board

    • Tenure: 2.2yrs
    • Compensation: €221.00k
  • Daniela Favoccia (55yo)

    Member of Supervisory Board

    • Tenure: 2.4yrs
    • Compensation: €46.00k
  • Thomas Scheper (63yo)

    Member of the Supervisory Board

    • Tenure: 7.4yrs
    • Compensation: €45.00k
  • Karoline Kleinschmidt (54yo)

    Member of the Supervisory Board

    • Tenure: 7.4yrs
    • Compensation: €46.00k
  • Manfred Zaffke (62yo)

    Vice Chairman of the Supervisory Board

    • Tenure: 5.5yrs
    • Compensation: €122.00k

Company Information

Sartorius Aktiengesellschaft's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Sartorius Aktiengesellschaft
  • Ticker: SART.F
  • Exchange: OTCPK
  • Founded: 1870
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: €11.561b
  • Listing Market Cap: €12.776b
  • Shares outstanding: 68.39m
  • Website: https://www.sartorius.com

Number of Employees


Location

  • Sartorius Aktiengesellschaft
  • Otto-Brenner-Strasse 20
  • Göttingen
  • Lower Saxony
  • 37079
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
0NIQLSE (London Stock Exchange)YesOrdinary SharesGBEURJan 1992
SART.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJan 1992
SRT3DB (Deutsche Boerse AG)Preference SharesDEEURJan 1992
SRTXTRA (XETRA Trading Platform)YesOrdinary SharesDEEURJan 1992
SRT3XTRA (XETRA Trading Platform)Preference SharesDEEURJan 1992
SRTDB (Deutsche Boerse AG)YesOrdinary SharesDEEURJan 1992
0NIRLSE (London Stock Exchange)Preference SharesGBEURJan 1992
SUVP.FOTCPK (Pink Sheets LLC)Preference SharesUSUSDJan 1992
SRT3DBATS-CHIXE (BATS 'Chi-X Europe')Preference SharesGBEURJan 1992
SRT3SWX (SIX Swiss Exchange)Preference SharesCHCHFJan 1992
SRT3WBAG (Wiener Boerse AG)Preference SharesATEURJan 1992

Biography

Sartorius Aktiengesellschaft supplies pharmaceutical and laboratory equipment worldwide. It operates in two divisions, Bioprocess Solutions, and Lab Products & Services. The company offers products for sus ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/20 00:33
End of Day Share Price2019/09/16 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.